Immunocore Holdings plc

NASDAQ:IMCR

Biotechnology

Healthcare
$27.51 +0.63%

+$0.18 today

Market cap
$1.42B
Beta
0.75
P/E (TTM)
-77.5
EPS (TTM)
-$0.37
52W Low $27.56High $40.72

Volume 0.30M

Average 0.40M

IMCR Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Immunocore Holdings plcNASDAQ: IMCR

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit grows in line with its trailing trend

Q1 FY2026 gross profit of $106.24M rose 14.2% year over year, behind the +15.4% change in trailing-twelve-month gross profit. Sequentially, it rose 42.0% from the prior quarter. Over 3 fiscal years it compounded at +28.0% a year.

Context

  • Gross profit amounted to 97.9% of revenue in FY2025, up 0.1 pp from a year earlier.
  • Gross profit increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +14.2% toward the trailing-twelve-month pace of +15.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$106.24M+42.0% QoQ
Last fiscal yearDec 2025
$291.36M+20.2% YoY
LTMMar 2026
$381.15M+15.4% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.2%——
1 year+20.2%——
3-year CAGR+28.0%——
5-year CAGR——
10-year CAGR——

Gross Profit history

Mixed currencies · from the income statement

Latest · FY2025
291.36M USD
Year-over-year change
+20.2%

Gross Profit vs competitors

How IMCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.4% is the 5th highest of 11, against a peer median of -34.0%.
  • Gross profit amounts to 98.8% of revenue for IMCR, versus a peer median of 91.0%.
IMCR Competitors
Gross Profit for IMCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€1.87B EUR-18.5%-46.9%70.8%
IMCRImmunocore Holdings plcLTM Mar 2026$381.15M USD+15.4%+28.0%98.8%
IBRXImmunityBio, Inc.LTM Sep 2026$176.5M USD+125.6%+676.9%96.7%
RCUSArcus Biosciences, Inc.LTM Jun 2026$110M USD-58.0%+28.4%94.0%
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M USD+16.2%-9.3%69.9%
CGENCompugen Ltd.LTM Mar 2026$63.98M USD+230.5%+113.5%88.1%
XNCRXencor, Inc.LTM Jun 2026$45.46M USD-54.8%—43.3%
IMTXImmatics N.V.LTM Mar 2026€37.3M EUR-74.1%-9.9%100.0%
JANXJanux Therapeutics, Inc.LTM Mar 2026$11.7M USD+129.7%+0.9%54.1%
IPHAInnate Pharma S.A.FY2025€2.79M EUR-77.9%-22.6%100.0%
IMMPImmutep LimitedFY2025-A$56.37M AUD-49.5%—1117.6%
Peer median (excluding IMCR) —-34.0%-4.2%91.0%

Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue27.04M144.23M197.39M247.98M297.57M
Cost of Revenue05.29M820.63K5.54M6.21M
Gross Profit27.04M138.94M196.57M242.44M291.36M
Gross Margin100.0%96.3%99.6%97.8%97.9%
Research & Development74.31M84.31M129.42M177.44M204.47M
Selling, General & Admin82.15M0114.35M121.17M120.62M
Operating Expenses156.46M181.71M243.77M298.77M325.09M
Depreciation & Amortization5.63M4.41M3.24M3.36M2.43M
EBITDA(123.58M)(38.35M)(40.87M)(38.5M)387.18K
EBITDA Margin-457.0%-26.6%-20.7%-15.5%0.1%
Operating Income(129.42M)(42.77M)(47.2M)(56.28M)(33.74M)
Operating Margin-478.5%-29.7%-23.9%-22.7%-11.3%
Interest Income65K3.76M14.23M25.62M16.48M
Interest Expense5.57M5.41M4.08M18.84M12.17M
Other Income / Expenses(3.92M)8.95M(982.07K)14.01M19.53M
Income Before Tax(133.34M)(33.82M)(48.19M)(42.32M)(14.21M)
Pre-Tax Margin-493.0%-23.4%-24.4%-17.1%-4.8%
Income Tax Expense111.19K9.65M(4.43M)(1.48M)12.21M
Net Income(133.45M)(43.46M)(43.75M)(40.81M)(26.42M)
Net Margin-493.4%-30.1%-22.2%-16.5%-8.9%
EPS (Basic)(3.13)(0.95)(0.89)(1.02)(0.53)
EPS (Diluted)(3.00)(0.95)(0.89)(1.02)(0.53)
Weighted Avg Shares42.49M45.71M48.89M49.99M50.35M
Weighted Avg Shares (Diluted)43.86M45.71M48.89M49.99M50.35M

Immunocore Holdings plc

NASDAQ:IMCR

Intrinsic Alpha fair value

Locked

Current Price

$27.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.